# EDGAR Filing Document

**Accession Number:** 0000874015
**File Stem:** 0001140361-26-017637
**Filing Date:** 2026-4
**Character Count:** 33553
**Document Hash:** 8a35b4a5106ae90b5ea6428af583c954
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001140361-26-017637.hdr.sgml**: 20260429

**ACCESSION NUMBER**: 0001140361-26-017637

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20260429

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260429

**DATE AS OF CHANGE**: 20260429

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** IONIS PHARMACEUTICALS INC
- **CENTRAL INDEX KEY:** 0000874015
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 330336973
- **STATE OF INCORPORATION:** CA
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-19125
- **FILM NUMBER:** 26910464

**BUSINESS ADDRESS:**
- **STREET 1:** 2855 GAZELLE COURT
- **CITY:** CARLSBAD
- **STATE:** CA
- **ZIP:** 92010
- **BUSINESS PHONE:** 7609319200

**MAIL ADDRESS:**
- **STREET 1:** 2855 GAZELLE COURT
- **CITY:** CARLSBAD
- **STATE:** CA
- **ZIP:** 92010

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ISIS PHARMACEUTICALS INC
- **DATE OF NAME CHANGE:** 19930328

?xml version='1.0' encoding='ASCII'?

------

### SECURITIES AND EXCHANGE COMMISSION

#### Washington, D.C. 20549

### FORM 8-K

#### CURRENT REPORT

#### PURSUANT TO SECTION 13 OR 15(d) OF THE

#### SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): April 29, 2026

## IONIS PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Charter)

#### Delaware
(State or Other Jurisdiction of Incorporation)

---

| | |
|:---|:---|
| **000-19125**<br>| **33-0336973** |
| (Commission File No.) | (IRS Employer Identification No.) |

---

#### 2855 Gazelle Court

#### Carlsbad, CA 92010
(Address of Principal Executive Offices and Zip Code)

Registrant's telephone number, including area code: **(760) 931-9200**

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading symbol | Name of each exchange on which registered |
| Common Stock, $.001 Par Value<br>| "IONS" | The Nasdaq Stock Market, LLC<br>|

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (Section 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (Section 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

---

| | |
|:---|:---|
| **Item 2.02** | **Results of Operations and Financial Condition.** |

---

On April 29, 2026, Ionis Pharmaceuticals, Inc. (the "***Company***") issued a press release announcing the Company's financial results for the quarter ended March 31, 2026. In addition to disclosing results that are determined in accordance with Generally Accepted Accounting Principles ("***GAAP***"), the Company also discloses pro forma or non-GAAP results of operations, which are adjusted from GAAP to exclude non-cash compensation expense related to equity awards and the related tax effects. The Company is presenting pro forma information excluding non-cash compensation expense related to equity awards and the related tax effects because the Company believes it better enables financial statement users to assess and compare its historical performance and project its future operating results and cash flows. A copy of the release is furnished with this report as an exhibit pursuant to "Item 2.02. Results of Operations and Financial Condition" of Form 8-K in accordance with SEC Release Nos. 33-8216 and 34-47583.

The information in this Current Report on Form 8-K and the Exhibit attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "***Exchange Act***") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing.

---

| | |
|:---|:---|
| **Item 9.01.** | **Financial Statements and Exhibits.** |

---

(d) Exhibits.

---

| | |
|:---|:---|
| **<u>Exhibit No.</u>** | **<u>Description</u>** |
| [99.1](ef20071749_ex99-1.htm) | Press Release dated April 29, 2026. |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |

---

------

#### SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **Ionis Pharmaceuticals, Inc.** | **Ionis Pharmaceuticals, Inc.** |
| Dated: April 29, 2026 | By: | /s/ Patrick R. O'Neil |
|  |  | **Patrick R. O'Neil** |
|  |  | Executive Vice President, Chief Legal Officer and General Counsel |

---

------

## Exhibit 99.1

------

#### Exhibit 99.1

![](image0.jpg)

#### Ionis reports first quarter 2026 financial results and highlights progress on key programs

*- TRYNGOLZA<sup>®</sup> (olezarsen) showed increasing demand in FCS driven by strong launch execution –*

*- Olezarsen sNDA accepted by the FDA for Priority Review; sHTG launch preparations on track –*

*– Increasing annual TRYNGOLZA peak net sales guidance to >$3B for sHTG –*

*- Zilganersen NDA for Alexander disease accepted for Priority Review, paving way for Ionis' first independent launch from leading neurology pipeline –*

*- Strong first-quarter performance and outlook for the year supports improved 2026 financial guidance -*

**CARLSBAD, Calif., April 29, 2026** – Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the "Company") today reported financial results and provided key updates for the first quarter ended March 31, 2026.

"Ionis' strong performance in the first quarter of 2026 underscores the strength of our commercial and R&D engines. Our independent launches are increasingly contributing to revenue, driven by strong commercial execution, and we are on track for two additional groundbreaking independent launches in 2026 — olezarsen for severe hypertriglyceridemia, our first medicine for a broad patient population, and zilganersen for Alexander disease, the first launch from our leading neurology pipeline," said Brett P. Monia, Ph.D., chief executive officer of Ionis. "In addition, we look forward to multiple key value-driving events this year, including results from pivotal Phase 3 partnered programs. These include presentation of positive bepirovirsen data in chronic hepatitis B next month at EASL, as well as results from the landmark pelacarsen Lp(a) HORIZON and eplontersen CARDIO-TTRansform cardiovascular outcomes trials later this year."

------

#### First Quarter 2026 Summary Financial Results<sup>(1)</sup>:

---

| | | |
|:---|:---|:---|
|  | Three months<br> ended<br> March 31, | Three months<br> ended<br> March 31, |
|  | 2026 | 2025 |
|  | (amounts in<br> millions) | (amounts in<br> millions) |
| Total revenue | $246 | $132 |
| Operating expenses | $364 | $278 |
| Operating expenses on a non-GAAP basis | $321 | $249 |
| Loss from operations | $(118) | $(146) |
| Loss from operations on a non-GAAP basis | $(75) | $(117) |

---

<br> (1) Reconciliation of GAAP to non-GAAP basis contained later in this release.

#### First Quarter 2026 Financial Highlights
&nbsp;&nbsp;&nbsp;&nbsp;• Revenue increased 87% in the first quarter of 2026 compared to the same period last year, driven by continued commercial success. In addition, Ionis earned substantial R&D revenue, including $95 million in payments from both clinical
 and regulatory milestones from multiple partnerships

&nbsp;&nbsp;&nbsp;&nbsp;• Operating expenses for the quarter ended March 31, 2026 were in line with expectations and increased year over year primarily from investments related to the commercialization efforts for TRYNGOLZA and DAWNZERA as well as launch
 preparations for olezarsen in sHTG and zilganersen in Alexander disease

&nbsp;&nbsp;&nbsp;&nbsp;• Cash and short-term investments were $1.9 billion as of March 31, 2026. The change in cash and short-term investments from year end 2025 was primarily related to the $633 million the Company used for the maturity of the 0% convertible
 notes due on April 1, 2026

&nbsp;&nbsp;&nbsp;&nbsp;• Increasing annual olezarsen peak net sales guidance to >$3 billion from >$2 billion to reflect increasing confidence in the sHTG market opportunity for olezarsen

#### First Quarter 2026 Financial Results
"Ionis entered 2026 with strong momentum. We continued this momentum with the first quarter financial results reflecting increased commercial revenue from our independent launches and robust R&D revenue when compared to the same period last year," said Elizabeth L. Hougen, chief financial officer of Ionis. "Based on our strong year-to-date revenue performance, accelerating momentum and positive outlook for the rest of the year, we are improving our 2026 financial guidance. The strong performance we expect in 2026 will support substantial growth and long-term value creation and our goal of reaching cash-flow breakeven in 2028."

#### Recent Highlights - Wholly Owned Medicines

&nbsp;&nbsp;&nbsp;&nbsp;• TRYNGOLZA<sup>®</sup> (olezarsen), the first FDA-approved treatment for adults living with familial chylomicronemia syndrome (FCS) as an adjunct to diet

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;o | Generated U.S. net product sales of $27 million in the first quarter of 2026, reflecting continued strong demand, offset by a decrease in net price |

---

------

<br> o Launch initiated in the European Union (EU) by Sobi

&nbsp;&nbsp;&nbsp;&nbsp;• Olezarsen on track to launch this year as a transformational medicine for severe hypertriglyceridemia (sHTG), assuming approval

<br> o sNDA accepted by the FDA for Priority Review for the treatment of sHTG with a Prescription Drug User Fee Act (PDUFA) target action date of June 30, 2026

<br> o The European Medicines Agency (EMA) accepted an indication extension application in March for the treatment of adult patients with sHTG

&nbsp;&nbsp;&nbsp;&nbsp;• DAWNZERA™ (donidalorsen), the first and only RNA-targeted prophylactic therapy for hereditary angioedema (HAE) in patients 12 years of age and older

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;o | Generated U.S. net product sales of $16 million in the first quarter of 2026, an increase of 125% versus the fourth quarter of 2025 |

---

<br> o Launch initiated in the EU by Otsuka

<br> o Positive one-year results from OASISplus open-label extension cohort published in the *Journal of Asthma and Allergy*

&nbsp;&nbsp;&nbsp;&nbsp;• Zilganersen on track to launch this year as the first and only medicine to demonstrate clinically meaningful and disease-modifying benefit in children and adults with Alexander disease (AxD), assuming approval

<br> o New Drug Application (NDA) for AxD accepted by FDA for Priority Review with PDUFA target action date of September 22, 2026

<br> o Expanded access program (EAP) in U.S. underway

<br> o Positive additional results from the pivotal study presented at the American Academy of Neurology 2026 annual meeting

#### Recent Highlights – Partnered Medicines
&nbsp;&nbsp;&nbsp;&nbsp;• SPINRAZA<sup>®</sup> (nusinersen) for the treatment of spinal muscular atrophy (SMA) generated global sales of $374
 million in the first quarter of 2026, resulting in royalty revenue of $44 million

<br> o SPINRAZA high dose regimen approved and launched in the U.S. and EU

&nbsp;&nbsp;&nbsp;&nbsp;• WAINUA<sup>®</sup> (eplontersen) (WAINZUA in EU) for the treatment of adults
 with polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTRv-PN) generated global sales of $51 million in the first quarter of 2026, resulting in royalty revenue of $11 million

<br> o Launches underway in numerous regions, including the EU and China; submissions in progress to expand WAINUA access globally

<br> o Phase 3 CARDIO-TTRansform study design and baseline characteristics to be presented at the Annual Congress of the Heart Failure Association of the ESC 2026

&nbsp;&nbsp;&nbsp;&nbsp;• Bepirovirsen, a potential first-in-class medicine for chronic hepatitis B (CHB), achieved the primary endpoint demonstrating a statistically significant and clinically meaningful functional cure rate in the B-Well 1 and B-Well 2 Phase 3
 studies

<br> o GSK to present the positive Phase 3 data at the European Association for the Study of the Liver (EASL) Congress 2026

------

<br> o On track for a 2026 launch with global regulatory filings underway, assuming approval

<br> ■ NDA filing accepted by FDA for Priority Review with PDUFA date of October 26, 2026; granted Breakthrough Therapy designation

<br> ■ Accepted for regulatory review in EU, Japan, and China

------

#### Revenue
Ionis' revenue was comprised of the following:

---

| | | |
|:---|:---|:---|
|  | Three months ended | Three months ended |
|  | March 31, | March 31, |
|  | 2026 | 2025 |
|  Revenue | (amounts in millions) | (amounts in millions) |
| &nbsp;&nbsp;&nbsp; Commercial revenue: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Product sales, net: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; TRYNGOLZA sales, net | $27 | $6 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; DAWNZERA sales, net | 16 | - |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total product sales, net | 43 | 6 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Royalty revenue: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPINRAZA royalties | 44 | 48 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; WAINUA royalties | 11 | 9 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other royalties | 3 | 7 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total royalty revenue | 58 | 64 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other commercial revenue | 7 | 6 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Total commercial revenue** | **108** | **76** |
| &nbsp;&nbsp;&nbsp; Research and development revenue: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Collaborative agreement revenue | 120 | 46 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; WAINUA joint development revenue | 18 | 10 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Total research and development revenue** | **138** | **56** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Total revenue** | $**246** | $**132** |

---

Commercial revenue for the first quarter ended March 31, 2026, increased 42%, compared to the same period in 2025. This increase was primarily driven by TRYNGOLZA and DAWNZERA product sales. Higher research and development revenue also contributed to the year-over-year revenue increase including approximately $95 million in milestone payments from multiple partnerships.

#### Operating Expenses
Operating expenses for the first quarter ended March 31, 2026, were driven from investments primarily related to commercialization efforts for TRYNGOLZA and DAWNZERA as well as launch preparations for olezarsen in sHTG and zilganersen in Alexander disease.

#### Balance Sheet
As of March 31, 2026, Ionis' cash, cash equivalents and short-term investments decreased to $1.9 billion, compared to $2.7 billion on December 31, 2025. At March 31, 2026, Ionis had an escrow deposit of $633 million, which the Company used for the maturity of its 0% convertible notes due on April 1, 2026.

------

#### 2026 Financial Guidance
Ionis improved its 2026 financial guidance to reflect the strong revenue performance experienced year-to-date and the Company's outlook for the balance of 2026. Overall, the Company increased total revenue and decreased operating loss both by $75 million. The improvements were driven by Priority Review for TRYNGOLZA, strong first quarter R&D revenue and the anticipated continued success of the Company's ongoing commercial launches.

---

| | | |
|:---|:---|:---|
| <br> Full Year 2026 Guidance | Previous<br> Guidance | New<br> Guidance |
| Total Revenue | $800-825 million | $875-900 million |
| TRYNGOLZA product sales, net | NA | $100-110 million |
| DAWNZERA product sales, net | NA | $110-120 million |
| Operating loss on a non-GAAP basis | $500-550 million | $425-475 million |
| Cash, cash equivalents and short-term investments | >$1.6 billion | >$1.6 billion |

---

#### Webcast and Other Updates

Management will host a conference call and webcast to discuss Ionis' first quarter 2026 results at 8:30 a.m. Eastern time on Wednesday, April 29, 2026. Interested parties may access the webcast <u>here</u>. A webcast replay will be available for a limited time at the same address. To access the Company's first quarter 2026 earnings slides click <u>here</u>.

#### Ionis' Marketed Medicines

#### INDICATION for TRYNGOLZA<sup>®</sup><sup></sup>(olezarsen)
TRYNGOLZA<sup>®</sup> (olezarsen) was approved by the U.S. Food and Drug Administration as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS).

#### IMPORTANT SAFETY INFORMATION

#### CONTRAINDICATIONS
TRYNGOLZA is contraindicated in patients with a history of serious hypersensitivity to TRYNGOLZA or any of the excipients in TRYNGOLZA. Hypersensitivity reactions requiring medical treatment have occurred.

#### WARNINGS AND PRECAUTIONS
Hypersensitivity Reactions

Hypersensitivity reactions (including symptoms of bronchospasm, diffuse erythema, facial swelling, urticaria, chills and myalgias) have been reported in patients treated with TRYNGOLZA. Advise patients on the signs and symptoms of hypersensitivity reactions and instruct patients to promptly seek medical attention and discontinue use of TRYNGOLZA if hypersensitivity reactions occur.

#### ADVERSE REACTIONS
The most common adverse reactions (incidence >5% of TRYNGOLZA-treated patients and >3% higher frequency than placebo) were injection site reactions, decreased platelet count and arthralgia.

Please see full <u>Prescribing Information</u> for TRYNGOLZA.

------

#### INDICATION for DAWNZERA<sup>TM</sup> (donidalorsen)

DAWNZERA™ (donidalorsen) was approved by the U.S. Food and Drug Administration for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age and older.

#### IMPORTANT SAFETY INFORMATION

#### CONTRAINDICATIONS

DAWNZERA is contraindicated in patients with a history of serious hypersensitivity reactions, including anaphylaxis, to donidalorsen or any of the excipients in DAWNZERA.

#### WARNINGS AND PRECAUTIONS

#### Hypersensitivity Reactions
Hypersensitivity reactions, including anaphylaxis, have been reported in patients treated with DAWNZERA. If signs and symptoms of serious hypersensitivity reactions occur, discontinue DAWNZERA and institute appropriate therapy.

#### ADVERSE REACTIONS
Most common adverse reactions (incidence ≥ 5%) are injection site reactions, upper respiratory tract infection, urinary tract infection, and abdominal discomfort.

Please see full <u>Prescribing Information</u> for DAWNZERA.

#### INDICATION for WAINUA<sup>®</sup> (eplontersen)
WAINUA injection, for subcutaneous use, 45 mg is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

**IMPORTANT SAFETY INFORMATION for WAINUA**<sup>®</sup> **(eplontersen)**

#### WARNINGS AND PRECAUTIONS
**Reduced Serum Vitamin A Levels and Recommended Supplementation** WAINUA leads to a decrease in serum vitamin A levels. Supplement with recommended daily allowance of vitamin A. Refer patient to an ophthalmologist if ocular symptoms suggestive of vitamin A deficiency occur.

#### ADVERSE REACTIONS
Most common adverse reactions (≥9% in WAINUA-treated patients) were vitamin A decreased (15%) and vomiting (9%).

Please see link to <u>U.S. Full Prescribing Information</u> for WAINUA.

For more information about SPINRAZA and QALSODY, visit <u>https://www.spinraza.com/</u> and <u>https://www.qalsody.com/</u>, respectively. QALSODY is approved under accelerated approval based on reduction in plasma neurofilament light chain (NfL) observed in patients treated with QALSODY. Continued approval may be contingent upon verification of clinical benefit in confirmatory trial(s).

------

#### About Ionis Pharmaceuticals, Inc.
For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has marketed medicines and a leading pipeline in neurology, cardiometabolic disease and select areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients. To learn more about Ionis, visit <u>Ionis.com</u> and follow us on <u>X (Twitter)</u><u>,</u> <u>LinkedIn</u> and <u>Instagram</u>.

#### Ionis Forward-looking Statements
This press release includes forward-looking statements regarding Ionis' business, financial guidance and the therapeutic and commercial potential of our commercial medicines, additional medicines in development, technologies and our expectations regarding development and regulatory milestones. Any statement describing Ionis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties including those inherent in the process of discovering, developing and commercializing medicines that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such medicines. Ionis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Ionis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Ionis. Except as required by law, we undertake no obligation to update any forward-looking statements for any reason. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Ionis' programs are described in additional detail in Ionis' annual report on Form 10-K for the year ended December 31, 2025, and most recent Form 10-Q, which are on file with the Securities and Exchange Commission. Copies of these and other documents are available from the Company.

In this press release, unless the context requires otherwise, "Ionis," "Company," "we," "our" and "us" all refer to Ionis Pharmaceuticals and its subsidiaries.

IONIS<sup>®</sup> is a registered trademark of Ionis Pharmaceuticals, Inc. TRYNGOLZA<sup>®</sup> is a registered trademark of Ionis Pharmaceuticals, Inc. DAWNZERA<sup>TM</sup> is a trademark of Ionis Pharmaceuticals, Inc. AKCEA<sup>TM</sup> is a trademark of Akcea Therapeutics, Inc. TEGSEDI<sup>TM</sup> is a trademark of Akcea Therapeutics, Inc. WAYLIVRA<sup>TM</sup> is a trademark of Akcea Therapeutics, Inc. SPINRAZA<sup>®</sup> and QALSODY<sup>®</sup> are registered trademarks of Biogen. WAINUA<sup>®</sup> is a registered trademark of the AstraZeneca group of companies.

#### Ionis Investor Contact:
D. Wade Walke, Ph.D.

<u>IR@ionis.com</u>

760-603-2331

#### Ionis Media Contact:
Hayley Soffer

<u>media@ionis.com</u>

760-603-4679

------

#### IONIS PHARMACEUTICALS, INC.

#### SELECTED FINANCIAL INFORMATION

#### Condensed Consolidated Statements of Operations

#### (In Millions, Except Per Share Data)

---

| | | |
|:---|:---|:---|
|  | Three months ended | Three months ended |
|  | March 31, | March 31, |
|  | 2026 | 2025 |
|  | (unaudited) | (unaudited) |
|  Revenue: |  |  |
| &nbsp;&nbsp;&nbsp; Commercial revenue: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Product sales, net | $43 | $6 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Royalty revenue | 58 | 64 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other commercial revenue | 7 | 6 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total commercial revenue | 108 | 76 |
| &nbsp;&nbsp;&nbsp; Research and development revenue: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Collaborative agreement revenue | 120 | 46 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; WAINUA joint development revenue | 18 | 10 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total research and development revenue | 138 | 56 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total revenue | 246 | 132 |
|  Expenses: |  |  |
| &nbsp;&nbsp;&nbsp; Cost of sales | 3 | 1 |
| &nbsp;&nbsp;&nbsp; Research, development and patent | 210 | 201 |
| &nbsp;&nbsp;&nbsp; Selling, general and administrative | 151 | 76 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total operating expenses | 364 | 278 |
|  Loss from operations | (118) | (146) |
|  Other income (expense): |  |  |
| &nbsp;&nbsp;&nbsp; Interest expense related to the sale of future royalties | (17) | (19) |
| &nbsp;&nbsp;&nbsp; Other income, net | 42 | 18 |
|  Loss before income tax expense | (93) | (147) |
|  Income tax expense | - | - |
|  Net loss | $(93) | $(147) |
|  Basic and diluted net loss per share | $(0.56) | $(0.93) |
|  Shares used in computing basic and diluted net loss per share | 165 | 159 |

---

------

#### IONIS PHARMACEUTICALS, INC.

#### Reconciliation of GAAP to Non-GAAP Basis:

#### Condensed Consolidated Operating Expenses, Loss From Operations, and Net Loss

#### (In Millions)

---

| | | |
|:---|:---|:---|
|  | Three months ended<br> March 31, | Three months ended<br> March 31, |
|  | 2026 | 2025 |
|  | (unaudited) | (unaudited) |
|  **As reported cost of sales according to GAAP** | $3 | $1 |
| &nbsp;&nbsp;&nbsp; Excluding compensation expense related to equity awards (1) | - | - |
|  **Non-GAAP cost of sales** | $3 | $1 |
|  **As reported research, development and patent expenses according to GAAP** | $210 | $201 |
| &nbsp;&nbsp;&nbsp; Excluding compensation expense related to equity awards | (25) | (20) |
|  **Non-GAAP research, development and patent expenses** | $185 | $181 |
|  **As reported selling, general and administrative expenses according to GAAP** | $151 | $76 |
| &nbsp;&nbsp;&nbsp; Excluding compensation expense related to equity awards | (18) | (9) |
|  **Non-GAAP selling, general and administrative expenses** | $133 | $67 |
|  **As reported operating expenses according to GAAP** | $364 | $278 |
| &nbsp;&nbsp;&nbsp; Excluding compensation expense related to equity awards | (43) | (29) |
|  **Non-GAAP operating expenses** | $321 | $249 |
|  **As reported loss from operations according to GAAP** | $(118) | $(146) |
| &nbsp;&nbsp;&nbsp; Excluding compensation expense related to equity awards | (43) | (29) |
|  **Non-GAAP loss from operations** | $(75) | $(117) |
|  **As reported net loss according to GAAP** | $(93) | $(147) |
| &nbsp;&nbsp;&nbsp; Excluding compensation expense related to equity awards and related tax effects | (43) | (29) |
|  **Non-GAAP net loss** | $(50) | $(118) |

---

<sup>(1)</sup> Amounts appear as zero due to rounding in millions.<br>

------

#### Reconciliation of GAAP to Non-GAAP Basis
As illustrated in the Selected Financial Information in this press release, non-GAAP operating expenses, non-GAAP loss from operations, and non-GAAP net loss were adjusted from GAAP to exclude compensation expense related to equity awards and the related tax effects. Compensation expense related to equity awards are non-cash. These measures are provided as supplementary information and are not a substitute for financial measures calculated in accordance with GAAP. Ionis reports these non-GAAP results to better enable financial statement users to assess and compare its historical performance and project its future operating results and cash flows. Further, the presentation of Ionis' non-GAAP results is consistent with how Ionis' management internally evaluates the performance of its operations.

------

#### IONIS PHARMACEUTICALS, INC.

#### Condensed Consolidated Balance Sheets

#### (In Millions)

---

| | | |
|:---|:---|:---|
|  | March 31,<br>2026 | December 31,<br>2025 |
|  | (unaudited) | |
|  Assets: |  |  |
| &nbsp;&nbsp;&nbsp; Cash, cash equivalents and short-term investments | $1919 | $2677 |
| &nbsp;&nbsp;&nbsp; Escrow deposits | 633 | - |
| &nbsp;&nbsp;&nbsp; Contracts receivable | 74 | 66 |
| &nbsp;&nbsp;&nbsp; Other current assets | 312 | 247 |
| &nbsp;&nbsp;&nbsp; Property, plant and equipment, net | 142 | 123 |
| &nbsp;&nbsp;&nbsp; Right-of-use assets | 235 | 239 |
| &nbsp;&nbsp;&nbsp; Other assets | 135 | 172 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total assets | $3450 | $3524 |
|  Liabilities and stockholders' equity: |  |  |
| &nbsp;&nbsp;&nbsp; Current portion of deferred contract revenue | $69 | $74 |
| &nbsp;&nbsp;&nbsp; 0% convertible senior notes due April 2026 – current | 433 | 432 |
| &nbsp;&nbsp;&nbsp; Other current liabilities | 215 | 277 |
| &nbsp;&nbsp;&nbsp; 0% convertible senior notes due 2030, net | 752 | 751 |
| &nbsp;&nbsp;&nbsp; 1.75% convertible senior notes due 2028, net | 569 | 568 |
| &nbsp;&nbsp;&nbsp; Liability related to sale of future royalties, net | 558 | 551 |
| &nbsp;&nbsp;&nbsp; Long-term lease liabilities | 259 | 262 |
| &nbsp;&nbsp;&nbsp; Long-term obligations, less current portion | 28 | 28 |
| &nbsp;&nbsp;&nbsp; Long-term deferred contract revenue | 76 | 92 |
| &nbsp;&nbsp;&nbsp; Total stockholders' equity | 491 | 489 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total liabilities and stockholders' equity | $3450 | $3524 |

---

------

**Key 2026 Value Driving Events**<sup>(1)</sup>

---

| | | | |
|:---|:---|:---|:---|
| **New Product Launches** | **New Product Launches** | **New Product Launches** | **New Product Launches** |
| **Program** | **Indication** | **Location** |  |
| DAWNZERA | HAE | EU | Achieved |
| Olezarsen | sHTG | U.S. | •  |
| Zilganersen | Alexander disease | U.S. | •  |
| Bepirovirsen | CHB | U.S. & Japan | •  |

---

---

| | | | |
|:---|:---|:---|:---|
| **Regulatory Actions** | **Regulatory Actions** | **Regulatory Actions** | **Regulatory Actions** |
| **Program** | **Indication** | **Regulatory Action** |  |
| Donidalorsen | HAE | EU approval decision | Achieved |
| Olezarsen | sHTG | U.S. approval decision | •  |
| Olezarsen | sHTG | EU submission | Achieved |
| Zilganersen | Alexander disease | U.S. submission | Achieved |
| Zilganersen | Alexander disease | U.S. approval decision | •  |
| Nusinersen<br> (high dose) | SMA | EU approval decision | Achieved |
| Nusinersen<br> (high dose) | SMA | U.S. approval decision | Achieved |
| Eplontersen | ATTR-CM | Regulatory submission(s) | •  |
| Bepirovirsen | HBV | Regulatory submission(s) | Achieved |
| Bepirovirsen | HBV | Regulatory decision(s) | •  |
| Pelacarsen | Lp(a)- CVD | U.S. submission | •  |

---

---

| | | | |
|:---|:---|:---|:---|
| **Key Phase 3 Clinical Events** | **Key Phase 3 Clinical Events** | **Key Phase 3 Clinical Events** | **Key Phase 3 Clinical Events** |
| **Program** | **Indication** | **Event** |  |
| Obudanersen | Angelman syndrome | Phase 3 enrollment completion | •  |
| Bepirovirsen | HBV | B-Well data | Achieved |
| Pelacarsen | Lp(a)-CVD | Lp(a) HORIZON data | •  |
| Eplontersen | ATTR-CM | CARDIO-TTRansform data | •  |
| Sefaxersen | IgAN | IMAGINATION data | •  |
| Ulefnersen | FUS-ALS | FUSION data | •  |
| Salanersen | SMA | Phase 3 initiation | •  |
| Sapablursen | Polycythemia Vera | Phase 3 initiation | •  |

---

---

| | | | |
|:---|:---|:---|:---|
| **Key Phase 2 Clinical Events** | **Key Phase 2 Clinical Events** | **Key Phase 2 Clinical Events** | **Key Phase 2 Clinical Events** |
| **Program** | **Indication** | **Event** |  |
| IONIS-MAPT<sub>Rx</sub>/ BIIB080 | Alzheimer's disease | Phase 2 CELIA data | •  |
| Tominersen | Huntington's disease | Phase 2 GENERATION HD2 data | •  |
| Tonlamarsen | Uncontrolled hypertension | Phase 2 data | Achieved |

---

<br> (1) Timing expectations based on current assumptions and subject to change.

<br> • Indicates that the milestone is anticipated in 2026.

\# \# \#

------